343 related articles for article (PubMed ID: 25107284)
1. Treatment of cognitive dysfunction in major depressive disorder--a review of the preclinical evidence for efficacy of selective serotonin reuptake inhibitors, serotonin-norepinephrine reuptake inhibitors and the multimodal-acting antidepressant vortioxetine.
Pehrson AL; Leiser SC; Gulinello M; Dale E; Li Y; Waller JA; Sanchez C
Eur J Pharmacol; 2015 Apr; 753():19-31. PubMed ID: 25107284
[TBL] [Abstract][Full Text] [Related]
2. Vortioxetine: a New Treatment for Major Depressive Disorder.
Connolly KR; Thase ME
Expert Opin Pharmacother; 2016; 17(3):421-31. PubMed ID: 26679430
[TBL] [Abstract][Full Text] [Related]
3. [Pharmacological properties of vortioxetine and its pre-clinical consequences].
David DJ; Tritschler L; Guilloux JP; Gardier AM; Sanchez C; Gaillard R
Encephale; 2016 Feb; 42(1 Suppl 1):1S12-23. PubMed ID: 26879252
[TBL] [Abstract][Full Text] [Related]
4. Vortioxetine for the treatment of major depressive disorder.
Tritschler L; Felice D; Colle R; Guilloux JP; Corruble E; Gardier AM; David DJ
Expert Rev Clin Pharmacol; 2014 Nov; 7(6):731-45. PubMed ID: 25166025
[TBL] [Abstract][Full Text] [Related]
5. Lu AA21004, a novel multimodal antidepressant, produces regionally selective increases of multiple neurotransmitters--a rat microdialysis and electrophysiology study.
Pehrson AL; Cremers T; Bétry C; van der Hart MG; Jørgensen L; Madsen M; Haddjeri N; Ebert B; Sanchez C
Eur Neuropsychopharmacol; 2013 Feb; 23(2):133-45. PubMed ID: 22612991
[TBL] [Abstract][Full Text] [Related]
6. VORTIOXETINE - THE NEW ANTIDEPRESSANT AGENT WITH PROCOGNITIVE PROPERTIES.
Dziwota E; Olajossy M
Acta Pol Pharm; 2016 Nov; 73(6):1433-1437. PubMed ID: 29634095
[TBL] [Abstract][Full Text] [Related]
7. Vortioxetine : a review of efficacy, safety and tolerability with a focus on cognitive symptoms in major depressive disorder.
Al-Sukhni M; Maruschak NA; McIntyre RS
Expert Opin Drug Saf; 2015 Aug; 14(8):1291-304. PubMed ID: 26022537
[TBL] [Abstract][Full Text] [Related]
8. Regional distribution of serotonergic receptors: a systems neuroscience perspective on the downstream effects of the multimodal-acting antidepressant vortioxetine on excitatory and inhibitory neurotransmission.
Pehrson AL; Jeyarajah T; Sanchez C
CNS Spectr; 2016 Apr; 21(2):162-83. PubMed ID: 26250622
[TBL] [Abstract][Full Text] [Related]
9. Current and Future Perspectives on the Major Depressive Disorder: Focus on the New Multimodal Antidepressant Vortioxetine.
Orsolini L; Tomasetti C; Valchera A; Iasevoli F; Buonaguro EF; Fornaro M; Fiengo ALC; Martinotti G; Vellante F; Matarazzo I; Vecchiotti R; Perna G; Di Nicola M; Carano A; Di Bartolomeis A; De Giannantonio M; De Berardis D
CNS Neurol Disord Drug Targets; 2017; 16(1):65-92. PubMed ID: 27781949
[TBL] [Abstract][Full Text] [Related]
10. Differential interaction with the serotonin system by S-ketamine, vortioxetine, and fluoxetine in a genetic rat model of depression.
du Jardin KG; Liebenberg N; Müller HK; Elfving B; Sanchez C; Wegener G
Psychopharmacology (Berl); 2016 Jul; 233(14):2813-25. PubMed ID: 27236785
[TBL] [Abstract][Full Text] [Related]
11. Other Antidepressants.
Schwasinger-Schmidt TE; Macaluso M
Handb Exp Pharmacol; 2019; 250():325-355. PubMed ID: 30194544
[TBL] [Abstract][Full Text] [Related]
12. Antidepressants and their effect on cognition in major depressive disorder.
Papakostas GI
J Clin Psychiatry; 2015 Aug; 76(8):e1046. PubMed ID: 26335095
[TBL] [Abstract][Full Text] [Related]
13. Vortioxetine promotes maturation of dendritic spines in vitro: A comparative study in hippocampal cultures.
Waller JA; Chen F; Sánchez C
Neuropharmacology; 2016 Apr; 103():143-54. PubMed ID: 26702943
[TBL] [Abstract][Full Text] [Related]
14. Chronic vortioxetine treatment in rodents modulates gene expression of neurodevelopmental and plasticity markers.
Waller JA; Tamm JA; Abdourahman A; Pehrson AL; Li Y; Cajina M; Sánchez C
Eur Neuropsychopharmacol; 2017 Feb; 27(2):192-203. PubMed ID: 28108062
[TBL] [Abstract][Full Text] [Related]
15. What role for ▼vortioxetine?
Drug Ther Bull; 2016 Mar; 54(3):30-3. PubMed ID: 26966120
[TBL] [Abstract][Full Text] [Related]
16. Vortioxetine: A multimodal antidepressant or another selective serotonin reuptake inhibitor?
Keks NA; Hope J; Culhane C
Australas Psychiatry; 2015 Jun; 23(3):210-3. PubMed ID: 25907797
[TBL] [Abstract][Full Text] [Related]
17. Modes and nodes explain the mechanism of action of vortioxetine, a multimodal agent (MMA): actions at serotonin receptors may enhance downstream release of four pro-cognitive neurotransmitters.
Stahl SM
CNS Spectr; 2015 Dec; 20(6):515-9. PubMed ID: 26062986
[TBL] [Abstract][Full Text] [Related]
18. Vortioxetine: A review of the pharmacology and clinical profile of the novel antidepressant.
Sowa-Kućma M; Pańczyszyn-Trzewik P; Misztak P; Jaeschke RR; Sendek K; Styczeń K; Datka W; Koperny M
Pharmacol Rep; 2017 Aug; 69(4):595-601. PubMed ID: 28499187
[TBL] [Abstract][Full Text] [Related]
19. Serotonergic Regulation of Prefrontal Cortical Circuitries Involved in Cognitive Processing: A Review of Individual 5-HT Receptor Mechanisms and Concerted Effects of 5-HT Receptors Exemplified by the Multimodal Antidepressant Vortioxetine.
Leiser SC; Li Y; Pehrson AL; Dale E; Smagin G; Sanchez C
ACS Chem Neurosci; 2015 Jul; 6(7):970-86. PubMed ID: 25746856
[TBL] [Abstract][Full Text] [Related]
20. Antidepressant and anxiolytic potential of the multimodal antidepressant vortioxetine (Lu AA21004) assessed by behavioural and neurogenesis outcomes in mice.
Guilloux JP; Mendez-David I; Pehrson A; Guiard BP; Repérant C; Orvoën S; Gardier AM; Hen R; Ebert B; Miller S; Sanchez C; David DJ
Neuropharmacology; 2013 Oct; 73():147-59. PubMed ID: 23721744
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
